Methemoglobin (SpMet®) is part of Masimo Rainbow SET®, a noninvasive blood constituent monitoring platform that provides measurements that previously required invasive blood sampling and time-consuming laboratory analysis.
SpMet is a breakthrough measurement that helps clinicians noninvasively and immediately diagnose and treat patients with methemoglobinemia.
- > Methemoglobinemia is an important clinical condition, more common than generally believed, and is linked to increased morbidity and mortality1
- > Many procedures and drugs commonly used in clinical practice—including iNO therapy in neonates—have been documented as contributing to induced methemoglobinemia1
- > Methemoglobinemia occurs across all care areas and patient populations yet is often unrecognized and misdiagnosed1
- > SpMet may improve patient outcomes, increase clinical efficiency, and decrease the cost of care
"Acquired Methemoglobinemia is fairly common and causes morbidity and mortality in both the inpatient and outpatient settings. Acquired methemoglobinemia is often unrecognized and thus untreated."
- Dr. Rachel Ash-Bernal, et al.
- 1 Ash-Bernal R, Wise R, Wright SM. Acquired Methemoglobinemia. A Retrospective Series of 138 Cases at 2 Teaching Hospitals. Medicine 2004; 83: 265-272.
